These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16507397)

  • 21. Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer.
    Davies G; Salter J; Hills M; Martin LA; Sacks N; Dowsett M
    Clin Cancer Res; 2003 Jul; 9(7):2651-6. PubMed ID: 12855643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recall phenomenon following epirubicin.
    Wilson J; Carder P; Gooi J; Nishikawa H
    Clin Oncol (R Coll Radiol); 1999; 11(6):424-5. PubMed ID: 10663338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
    Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
    Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
    Vlastos G; Mirza NQ; Lenert JT; Hunt KK; Ames FC; Feig BW; Ross MI; Buzdar AU; Singletary SE
    Cancer; 2000 Mar; 88(6):1417-24. PubMed ID: 10717625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
    Chow LW; Tung SY; Ng TY; Im SA; Lee MH; Yip AY; Toi M; Glück S
    Expert Opin Investig Drugs; 2013 Mar; 22(3):299-307. PubMed ID: 23394482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.
    Ponthan F; Wickström M; Gleissman H; Fuskevåg OM; Segerström L; Sveinbjörnsson B; Redfern CP; Eksborg S; Kogner P; Johnsen JI
    Clin Cancer Res; 2007 Feb; 13(3):1036-44. PubMed ID: 17289900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
    Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
    Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tc-99m sestamibi scintimammography in the evaluation of response of breast carcinoma to chemotherapy.
    Joaquim AI; Sagarra AJ; Ramos CD; Coudry R; Sagarra RA; Camargo EE
    Clin Nucl Med; 1997 Sep; 22(9):638-40. PubMed ID: 9298303
    [No Abstract]   [Full Text] [Related]  

  • 31. Paradoxical effect of cytotoxic chemotherapy on anemia in cancer patients with beta-thalassemia minor.
    Del Mastro L; Venturini M; Costantini M; Garrone O; Sertoli MR; Bertelli G; Machì AM; Rosso R
    J Natl Cancer Inst; 1997 Mar; 89(6):455-6. PubMed ID: 9091649
    [No Abstract]   [Full Text] [Related]  

  • 32. Coincidential successful treatment of Jessner-Kanof disease with chemotherapy.
    Ardavanis A; Orphanos G; Skafida S; Basioukas S; Rigatos G
    Ann Oncol; 2008 Jul; 19(7):1360-1361. PubMed ID: 18534961
    [No Abstract]   [Full Text] [Related]  

  • 33. Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy.
    Mottolese M; Benevolo M; Del Monte G; Buglioni S; Papaldo P; Nisticò C; Di Filippo F; Vasselli S; Vici P; Botti C
    J Cancer Res Clin Oncol; 2000 Dec; 126(12):722-9. PubMed ID: 11153146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patients' concerns about clinical trials in Japan.
    Aoki E
    Lancet; 1999 Mar; 353(9157):1019-20. PubMed ID: 10459946
    [No Abstract]   [Full Text] [Related]  

  • 35. Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53.
    Katkoori VR; Manne K; Vital-Reyes VS; Rodríguez-Burford C; Shanmugam C; Sthanam M; Manne U; Chatla C; Abdulkadir SA; Grizzle WE
    Biotech Histochem; 2013 Jan; 88(1):38-46. PubMed ID: 23167625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.
    Rahman M; Selvarajan K; Hasan MR; Chan AP; Jin C; Kim J; Chan SK; Le ND; Kim YB; Tai IT
    Neoplasia; 2012 Jul; 14(7):624-33. PubMed ID: 22904679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
    Basu GD; Pathangey LB; Tinder TL; Gendler SJ; Mukherjee P
    Breast Cancer Res; 2005; 7(4):R422-35. PubMed ID: 15987447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.
    Ohtsu N; Takaoka K; Segawa E; Hashitani S; Noguchi K; Kishimoto H; Urade M
    Oncol Rep; 2010 Jul; 24(1):31-6. PubMed ID: 20514441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
    Lehmann-Che J; André F; Desmedt C; Mazouni C; Giacchetti S; Turpin E; Espié M; Plassa LF; Marty M; Bertheau P; Sotiriou C; Piccart M; Symmans WF; Pusztai L; de Thé H
    Oncologist; 2010; 15(3):246-52. PubMed ID: 20228131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: a phase II TCOG study.
    Wang LW; Hsiao CF; Chen WT; Lee HH; Lin TC; Chen HC; Chen HH; Chien CR; Lin TY; Liu TW
    J Surg Oncol; 2014 May; 109(6):580-5. PubMed ID: 24374744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.